Latest Acasti Pharma Inc (ACST) Headlines
How Gunmen Killed 43 Students in Yobe
All Africa Global Media - Wed Feb 26, 1:32AM CST
Boko Haram cowards yesterday killed about 43 innocent students of the Federal Government College (FGC), Buni-Yadi in Gujba local government area of Yobe State.
Omega-3 Polyunsaturated Fatty Acids (PUFAs) - 2014 Global Market Overview
M2 - Tue Feb 25, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/mb5wq7/omega3) has announced the addition of the "Omega-3 Polyunsaturated Fatty Acids (PUFAs) - A Global Market Overview" report to their offering. Pharmaceutical drugs, by default, have started incorporating higher concentrations of omega-3 and it is anticipated that, over the coming few years, several new companies would be jumping on to the bandwagon of omega-3 drugs. Several drugs are in Phase II or Phase III clinical trials, with several more expected to come on-stream quite soon. However, the coming year or two is likely to witness an influx of new companies invading the global omega-3 market, provided they obtain the USFDA's or other relevant authorities' approvals. In a global scenario where increasing attention is being directed towards issues of sustainability and limited food supplies, algal sources offer immense scope for the rapidly expanding omega-3 market to continue in the same vein. The focus on obtaining EPA and DHA from algae was prompted by an endeavor to seek out more sustainable sources, since EPA and DHA are naturally contained in algae. Moreover, the omega-3 content in fish and krill originates from their consuming the algae directly or other creatures that feed on algae. In addition to being sustainable, algae also allows for farming that can be of help in putting up desirable labels, such as vegetarian, kosher or even organic. The past several decades have been witness to research studies that have underscored the significance of omega-3 fatty acids in maintaining heart health, in addition to safeguarding against cancer and birth defects and offsetting symptoms of diabetes, arthritis, cognitive decline, depression and several other conditions. Omega-3 Polyunsaturated Fatty Acids (PUFAs) have been growing and continues to grow significantly in the future, attributed to the above benefits. The report reviews, analyses and projects the market of marine and algal omega-3 polyunsaturated fatty acid ingredients for global and the regional markets including North America, Europe, Asia-Pacific and Rest of World. The regional markets further analyzed for 13 independent countries. Omega-3 Polyunsaturated Fatty Acid (PUFAs) ingredients market analyzed in this study include EPA and DHA omega-3s from marine oils such as fish oils, krill oils and squid oils; and algal oils. The end use application markets covered in the report include dietary supplements, food & beverages, pet nutrition, infant nutrition, pharmaceuticals and clinical nutrition. Worldwide, consumption of Omega-3 polyunsaturated fatty acids (PUFAs), estimated at 123.8 thousand metric tons worth US$2.3 billion in 2013, is forecast to be 134.7 thousand metric tons valued at US$2.5 billion in 2014. By 2020, it is projected that demand for Omega-3 PUFAs globally would reach 241 thousand metric tons with a value of US$4.96 billion, thereby posting a volume CAGR of almost 10% and a value CAGR of 11.6% between 2013 and 2020. Key Topics Covered Part A: Global Market Perspective 1. Introduction 2. Global Regulatory Landscape For Omega-3 Fatty Acids 3. Key Market Trends 4. Industry Structure And Competetive Landscape 5. Key Global Players 6. Key Business Trends 7. Key Product/Technology Trends 8. Global Market Overview Part B: Regional Market Perspective 1. Global Omega-3 Pufas Market Overview By Geographic Region 2. Global Marine Omega-3 Pufas Market Overview By Geographic Region 3. Global Algal Omega-3 Pufas Market Overview By Geographic Region 4. Global Omega-3 Pufas End-Use Application Market Overview By Geographic Region Regional Market Overview 1. North America 2. Europe 3. Asia-Pacific 4. Rest Of World Part C: Omega-3 Patent Landscape 1. Fish Oil Omega-3 Fatty Acids 2. Algal Oil Omega-3 Fatty Acids Part D: Guide To The Industry 1. Manufacturers Of Omega 3 Ingredients 2. Pharma Companies In Omega 3 Drugs Market 3. Raw Material Producers, Omega 3 End Users And Other Related Companies In Omega 3 Industry 4. Major Ingredient Distributors Part E: Annexure 1. Research Methodology 2. The Questionnaire 3. Feedback Companies Mentioned Examples of companies mentioned include: - Acasti Pharma - Aker Biomarine - Algae Biosciences - Aurora Algae - Ayanda - BASF - Chemport - Croda International - GC Rieber Oils - Golden Omega - Hubei Fuxing Biotechnology - Jiangsu Auqi Marine Biotechnology - Marine Ingredients - Maruha Nichiro Foods - Neptune Technologies & Bioressources - Nippon Suisan Kaisha(Nissui) - Olvea Fish Oils (Olvea Group) - Omega Protein - Pharma Marine - Polaris Nutritional Lipids - Qualitas Health - Sinomega Biotech Engineering - Smit Functional Oils (Smit & Zoon Group) - Solutex GC - Source-Omega - Stepan - TASA Omega (Tecnol?gica De Alimentos) - Zhejiang Shenzhou Marine Bio-Tech ... and more For more information visit http://www.researchandmarkets.com/research/mb5wq7/omega3 About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
TSX Venture Exchange Daily Bulletins
CNW Group - Fri Feb 21, 5:26PM CST
TSX VENTURE COMPANIES:
Neptune and Acasti Provide Update on Patent Litigations With Enzymotec
GlobeNewswire - Fri Feb 14, 8:52AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti") (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec") that would resolve the International Trade Commission ("ITC") investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding.
Acasti and Neptune Provide Update on Patent Litigations with Enzymotec
GlobeNewswire - Fri Feb 14, 8:40AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti") (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec") that would resolve the International Trade Commission ("ITC") investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding.
Acasti Pharma Inc concludes CAD2.15m private placement
M2 - Mon Feb 10, 6:33AM CST
Biopharmaceutical company Acasti Pharma Inc (NasdaqCM:ACST) (TSX:APO.V) reported on Friday the completion of a private placement of CAD2,150,000 units at CAD1.33 per unit.
Acasti Announces Closing of CAD$2.15 Million Private Placement
GlobeNewswire - Fri Feb 07, 7:00AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announced today the closing of a private placement of CAD$2,150,000 of units of Acasti ("Units") at a price of CAD$1.33 per Unit, each Unit consisting of one (1) Class A share ("Common Share") and one (1) Common Share purchase warrant ("Warrant") of Acasti (the "Private Placement"). Each Warrant will entitle the holder to purchase one Common Share ("Warrant Share") at an exercise price of CAD$1.60 per Warrant Share, subject to adjustment, at any time until 5:00 p.m. (Montreal time) on December 3, 2018.
5 Stocks Under $10 Set to Soar
at The Street - Thu Feb 06, 2:15PM CST
These under-$10 stocks look ready to trade higher from current levels.
Acasti Announces Third Quarter Results
GlobeNewswire - Tue Jan 14, 6:29AM CST
Acasti Pharma ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), a Neptune Technologies & Bioressources Inc.'s ("Neptune") subsidiary, announces its financial results for the three and nine-month periods ended November 30, 2013.
FDA Clears Acasti's Investigational New Drug Submission to Conduct PK Trial
GlobeNewswire - Thu Jan 09, 6:30AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company, announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) submission to initiate a Pharmacokinetic (PK) trial of CaPrein the U.S., having found no objections with the PK trial design, protocol, or safety profile of CaPre. Following the clearance, Acasti engaged Quintiles, the world's largest provider of biopharmaceutical development and commercial outsourcing services, to conduct its PK study.
Acasti Appoints Jerald J. Wenker as Special Advisor and Nominee to Its Board of Directors
GlobeNewswire - Thu Dec 19, 6:30AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces the appointment of Jerald J. Wenker as a special advisor to its Board of Directors. Mr. Wenker has also accepted the nomination for election to serve on the Corporation's Board of Directors at the next Annual Meeting to be held in 2014, subject to shareholder approval, including increasing the maximum number of Board of Directors to at least 7 members from 6 currently.
Neptune, Acasti and Enzymotec Sign Settlement Term Sheet Resulting in Stay of ITC Investigation for 30 Days
GlobeNewswire - Wed Dec 18, 7:59AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti") (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that on December 16, 2013, the Administrative Law Judge presiding over the pending International Trade Commission (ITC) Investigation involving Neptune and Acasti; and Enzymotec Ltd., and Enzymotec USA, Inc. (collectively, "Enzymotec") granted the parties' joint motion to stay the proceedings for thirty days. The investigation was instituted earlier this year by Neptune and Acasti in a complaint filed with the ITC alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players.
Neptune and Aker BioMarine Reach Patent Infringement Settlement and License Agreement
GlobeNewswire - Tue Dec 17, 7:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB), Acasti Pharma Inc. ("Acasti") (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, and Aker BioMarine AS, Aker BioMarine Antarctic AS and Aker BioMarine Antarctic USA (collectively "AKBM") jointly announce a settlement and license agreement that will result in the dismissal of all AKBM respondents from the on-going ITC investigation brought by Neptune and Acasti, as well as the dismissal of all current lawsuits brought by Neptune against AKBM and companies in its value chain.
Nasdaq stocks posting largest volume increases
AP - Fri Dec 13, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Acasti Pharma Inc concludes offering of USD23m units
M2 - Wed Dec 04, 4:48AM CST
Biopharmaceutical company Acasti Pharma Inc (NasdaqCM:ACST) (TSXV :APO.V) reported on Tuesday the completion of its public offering of 16,000,000 units at a price of USD1.25 per unit.
Neptune Participates in the Equity Financing of Acasti Pharma
GlobeNewswire - Tue Dec 03, 2:13PM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX:NTB) announces that it acquired securities of its subsidiary Acasti Pharma Inc. ("Acasti") in connection with the closing of Acasti's US$23 million public offering (the "Offering") of units ("Units"), which closed today and pursuant to which 18.4 million Units were issued.
Acasti Announces Closing of US$23 Million Underwritten Offering of Units
GlobeNewswire - Tue Dec 03, 9:14AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announced today the closing of its previously announced underwritten public offering of 16,000,000 units of Acasti ("Units") at a price of US$1.25 per Unit, each Unit consisting of one (1) Class A share ("Common Share") and one (1) Common Share purchase warrant ("Warrant") of Acasti. Each Warrant will entitle the holder to purchase one Common Share ("Warrant Share") at an exercise price of US$1.50 per Warrant Share, subject to adjustment, at any time until 5:00 p.m. (Montreal time) on the date that is the fifth anniversary of the closing of the offering. Prior to the closing, the underwriters exercised their over-allotment option in full to purchase an additional 2,400,000 Units, resulting in a total of 18,400,000 Units being issued today for gross proceeds of approximately US$23 million.
How Gunmen Killed 43 Students in Yobe
All Africa Global Media - Wed Feb 26, 1:32AM CST
Boko Haram cowards yesterday killed about 43 innocent students of the Federal Government College (FGC), Buni-Yadi in Gujba local government area of Yobe State.
Omega-3 Polyunsaturated Fatty Acids (PUFAs) - 2014 Global Market Overview
M2 - Tue Feb 25, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/mb5wq7/omega3) has announced the addition of the "Omega-3 Polyunsaturated Fatty Acids (PUFAs) - A Global Market Overview" report to their offering. Pharmaceutical drugs, by default, have started incorporating higher concentrations of omega-3 and it is anticipated that, over the coming few years, several new companies would be jumping on to the bandwagon of omega-3 drugs. Several drugs are in Phase II or Phase III clinical trials, with several more expected to come on-stream quite soon. However, the coming year or two is likely to witness an influx of new companies invading the global omega-3 market, provided they obtain the USFDA's or other relevant authorities' approvals. In a global scenario where increasing attention is being directed towards issues of sustainability and limited food supplies, algal sources offer immense scope for the rapidly expanding omega-3 market to continue in the same vein. The focus on obtaining EPA and DHA from algae was prompted by an endeavor to seek out more sustainable sources, since EPA and DHA are naturally contained in algae. Moreover, the omega-3 content in fish and krill originates from their consuming the algae directly or other creatures that feed on algae. In addition to being sustainable, algae also allows for farming that can be of help in putting up desirable labels, such as vegetarian, kosher or even organic. The past several decades have been witness to research studies that have underscored the significance of omega-3 fatty acids in maintaining heart health, in addition to safeguarding against cancer and birth defects and offsetting symptoms of diabetes, arthritis, cognitive decline, depression and several other conditions. Omega-3 Polyunsaturated Fatty Acids (PUFAs) have been growing and continues to grow significantly in the future, attributed to the above benefits. The report reviews, analyses and projects the market of marine and algal omega-3 polyunsaturated fatty acid ingredients for global and the regional markets including North America, Europe, Asia-Pacific and Rest of World. The regional markets further analyzed for 13 independent countries. Omega-3 Polyunsaturated Fatty Acid (PUFAs) ingredients market analyzed in this study include EPA and DHA omega-3s from marine oils such as fish oils, krill oils and squid oils; and algal oils. The end use application markets covered in the report include dietary supplements, food & beverages, pet nutrition, infant nutrition, pharmaceuticals and clinical nutrition. Worldwide, consumption of Omega-3 polyunsaturated fatty acids (PUFAs), estimated at 123.8 thousand metric tons worth US$2.3 billion in 2013, is forecast to be 134.7 thousand metric tons valued at US$2.5 billion in 2014. By 2020, it is projected that demand for Omega-3 PUFAs globally would reach 241 thousand metric tons with a value of US$4.96 billion, thereby posting a volume CAGR of almost 10% and a value CAGR of 11.6% between 2013 and 2020. Key Topics Covered Part A: Global Market Perspective 1. Introduction 2. Global Regulatory Landscape For Omega-3 Fatty Acids 3. Key Market Trends 4. Industry Structure And Competetive Landscape 5. Key Global Players 6. Key Business Trends 7. Key Product/Technology Trends 8. Global Market Overview Part B: Regional Market Perspective 1. Global Omega-3 Pufas Market Overview By Geographic Region 2. Global Marine Omega-3 Pufas Market Overview By Geographic Region 3. Global Algal Omega-3 Pufas Market Overview By Geographic Region 4. Global Omega-3 Pufas End-Use Application Market Overview By Geographic Region Regional Market Overview 1. North America 2. Europe 3. Asia-Pacific 4. Rest Of World Part C: Omega-3 Patent Landscape 1. Fish Oil Omega-3 Fatty Acids 2. Algal Oil Omega-3 Fatty Acids Part D: Guide To The Industry 1. Manufacturers Of Omega 3 Ingredients 2. Pharma Companies In Omega 3 Drugs Market 3. Raw Material Producers, Omega 3 End Users And Other Related Companies In Omega 3 Industry 4. Major Ingredient Distributors Part E: Annexure 1. Research Methodology 2. The Questionnaire 3. Feedback Companies Mentioned Examples of companies mentioned include: - Acasti Pharma - Aker Biomarine - Algae Biosciences - Aurora Algae - Ayanda - BASF - Chemport - Croda International - GC Rieber Oils - Golden Omega - Hubei Fuxing Biotechnology - Jiangsu Auqi Marine Biotechnology - Marine Ingredients - Maruha Nichiro Foods - Neptune Technologies & Bioressources - Nippon Suisan Kaisha(Nissui) - Olvea Fish Oils (Olvea Group) - Omega Protein - Pharma Marine - Polaris Nutritional Lipids - Qualitas Health - Sinomega Biotech Engineering - Smit Functional Oils (Smit & Zoon Group) - Solutex GC - Source-Omega - Stepan - TASA Omega (Tecnol?gica De Alimentos) - Zhejiang Shenzhou Marine Bio-Tech ... and more For more information visit http://www.researchandmarkets.com/research/mb5wq7/omega3 About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
TSX Venture Exchange Daily Bulletins
CNW Group - Fri Feb 21, 5:26PM CST
TSX VENTURE COMPANIES:
Neptune and Acasti Provide Update on Patent Litigations With Enzymotec
GlobeNewswire - Fri Feb 14, 8:52AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti") (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec") that would resolve the International Trade Commission ("ITC") investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding.
Acasti and Neptune Provide Update on Patent Litigations with Enzymotec
GlobeNewswire - Fri Feb 14, 8:40AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti") (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec") that would resolve the International Trade Commission ("ITC") investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding.
Acasti Pharma Inc concludes CAD2.15m private placement
M2 - Mon Feb 10, 6:33AM CST
Biopharmaceutical company Acasti Pharma Inc (NasdaqCM:ACST) (TSX:APO.V) reported on Friday the completion of a private placement of CAD2,150,000 units at CAD1.33 per unit.
Acasti Announces Closing of CAD$2.15 Million Private Placement
GlobeNewswire - Fri Feb 07, 7:00AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announced today the closing of a private placement of CAD$2,150,000 of units of Acasti ("Units") at a price of CAD$1.33 per Unit, each Unit consisting of one (1) Class A share ("Common Share") and one (1) Common Share purchase warrant ("Warrant") of Acasti (the "Private Placement"). Each Warrant will entitle the holder to purchase one Common Share ("Warrant Share") at an exercise price of CAD$1.60 per Warrant Share, subject to adjustment, at any time until 5:00 p.m. (Montreal time) on December 3, 2018.
5 Stocks Under $10 Set to Soar
at The Street - Thu Feb 06, 2:15PM CST
These under-$10 stocks look ready to trade higher from current levels.
Acasti Announces Third Quarter Results
GlobeNewswire - Tue Jan 14, 6:29AM CST
Acasti Pharma ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), a Neptune Technologies & Bioressources Inc.'s ("Neptune") subsidiary, announces its financial results for the three and nine-month periods ended November 30, 2013.
FDA Clears Acasti's Investigational New Drug Submission to Conduct PK Trial
GlobeNewswire - Thu Jan 09, 6:30AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company, announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) submission to initiate a Pharmacokinetic (PK) trial of CaPrein the U.S., having found no objections with the PK trial design, protocol, or safety profile of CaPre. Following the clearance, Acasti engaged Quintiles, the world's largest provider of biopharmaceutical development and commercial outsourcing services, to conduct its PK study.
Acasti Appoints Jerald J. Wenker as Special Advisor and Nominee to Its Board of Directors
GlobeNewswire - Thu Dec 19, 6:30AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces the appointment of Jerald J. Wenker as a special advisor to its Board of Directors. Mr. Wenker has also accepted the nomination for election to serve on the Corporation's Board of Directors at the next Annual Meeting to be held in 2014, subject to shareholder approval, including increasing the maximum number of Board of Directors to at least 7 members from 6 currently.
Neptune, Acasti and Enzymotec Sign Settlement Term Sheet Resulting in Stay of ITC Investigation for 30 Days
GlobeNewswire - Wed Dec 18, 7:59AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti") (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that on December 16, 2013, the Administrative Law Judge presiding over the pending International Trade Commission (ITC) Investigation involving Neptune and Acasti; and Enzymotec Ltd., and Enzymotec USA, Inc. (collectively, "Enzymotec") granted the parties' joint motion to stay the proceedings for thirty days. The investigation was instituted earlier this year by Neptune and Acasti in a complaint filed with the ITC alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players.
Neptune and Aker BioMarine Reach Patent Infringement Settlement and License Agreement
GlobeNewswire - Tue Dec 17, 7:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB), Acasti Pharma Inc. ("Acasti") (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, and Aker BioMarine AS, Aker BioMarine Antarctic AS and Aker BioMarine Antarctic USA (collectively "AKBM") jointly announce a settlement and license agreement that will result in the dismissal of all AKBM respondents from the on-going ITC investigation brought by Neptune and Acasti, as well as the dismissal of all current lawsuits brought by Neptune against AKBM and companies in its value chain.
Nasdaq stocks posting largest volume increases
AP - Fri Dec 13, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Acasti Pharma Inc concludes offering of USD23m units
M2 - Wed Dec 04, 4:48AM CST
Biopharmaceutical company Acasti Pharma Inc (NasdaqCM:ACST) (TSXV :APO.V) reported on Tuesday the completion of its public offering of 16,000,000 units at a price of USD1.25 per unit.
Neptune Participates in the Equity Financing of Acasti Pharma
GlobeNewswire - Tue Dec 03, 2:13PM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX:NTB) announces that it acquired securities of its subsidiary Acasti Pharma Inc. ("Acasti") in connection with the closing of Acasti's US$23 million public offering (the "Offering") of units ("Units"), which closed today and pursuant to which 18.4 million Units were issued.
Acasti Announces Closing of US$23 Million Underwritten Offering of Units
GlobeNewswire - Tue Dec 03, 9:14AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announced today the closing of its previously announced underwritten public offering of 16,000,000 units of Acasti ("Units") at a price of US$1.25 per Unit, each Unit consisting of one (1) Class A share ("Common Share") and one (1) Common Share purchase warrant ("Warrant") of Acasti. Each Warrant will entitle the holder to purchase one Common Share ("Warrant Share") at an exercise price of US$1.50 per Warrant Share, subject to adjustment, at any time until 5:00 p.m. (Montreal time) on the date that is the fifth anniversary of the closing of the offering. Prior to the closing, the underwriters exercised their over-allotment option in full to purchase an additional 2,400,000 Units, resulting in a total of 18,400,000 Units being issued today for gross proceeds of approximately US$23 million.
